
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, shares information on the current and future estimates of e-prescribing use.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, shares information on the current and future estimates of e-prescribing use.
This video was recorded at the 2015 NCPA Annual Convention.






